STERIS plc $STE Stock Holdings Increased by Vanguard Personalized Indexing Management LLC

Vanguard Personalized Indexing Management LLC raised its holdings in STERIS plc (NYSE:STE) by 48.8% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 12,585 shares of the medical equipment provider’s stock after acquiring an additional 4,128 shares during the quarter. Vanguard Personalized Indexing Management LLC’s holdings in STERIS were worth $3,024,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Geneos Wealth Management Inc. boosted its position in STERIS by 416.0% during the first quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 104 shares during the period. Grove Bank & Trust lifted its position in STERIS by 4,733.3% in the first quarter. Grove Bank & Trust now owns 145 shares of the medical equipment provider’s stock worth $33,000 after purchasing an additional 142 shares during the period. Zions Bancorporation National Association UT bought a new position in STERIS in the first quarter worth $37,000. ORG Wealth Partners LLC bought a new position in STERIS in the first quarter worth $43,000. Finally, Golden State Wealth Management LLC lifted its holdings in shares of STERIS by 503.0% during the first quarter. Golden State Wealth Management LLC now owns 199 shares of the medical equipment provider’s stock valued at $45,000 after acquiring an additional 166 shares during the period. 94.69% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

STE has been the subject of a number of analyst reports. Wall Street Zen raised STERIS from a “buy” rating to a “strong-buy” rating in a report on Sunday, September 14th. KeyCorp lifted their price objective on STERIS from $277.00 to $288.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 22nd. Weiss Ratings restated a “buy (b)” rating on shares of STERIS in a report on Tuesday. Finally, Morgan Stanley lifted their price objective on STERIS from $276.00 to $295.00 and gave the company an “overweight” rating in a report on Friday, August 8th. Seven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $273.50.

STERIS Stock Performance

Shares of NYSE STE opened at $236.71 on Thursday. The stock’s fifty day moving average price is $245.05 and its two-hundred day moving average price is $236.07. The firm has a market cap of $23.31 billion, a price-to-earnings ratio of 36.25 and a beta of 1.01. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.22 and a quick ratio of 1.53. STERIS plc has a one year low of $200.98 and a one year high of $253.00.

STERIS (NYSE:STE) last released its earnings results on Wednesday, August 6th. The medical equipment provider reported $2.34 earnings per share for the quarter, beating analysts’ consensus estimates of $2.32 by $0.02. The firm had revenue of $1.40 billion during the quarter, compared to the consensus estimate of $1.36 billion. STERIS had a return on equity of 14.17% and a net margin of 11.61%.The company’s revenue was up 8.8% compared to the same quarter last year. During the same period in the prior year, the company posted $2.03 EPS. On average, equities analysts forecast that STERIS plc will post 9.08 EPS for the current year.

STERIS Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 26th. Investors of record on Thursday, September 4th were given a dividend of $0.63 per share. The ex-dividend date was Thursday, September 4th. This represents a $2.52 annualized dividend and a dividend yield of 1.1%. This is an increase from STERIS’s previous quarterly dividend of $0.57. STERIS’s dividend payout ratio is currently 38.59%.

Insider Buying and Selling at STERIS

In other STERIS news, Director Cynthia L. Feldmann sold 3,495 shares of the stock in a transaction dated Monday, August 11th. The stock was sold at an average price of $241.56, for a total value of $844,252.20. Following the completion of the transaction, the director directly owned 705 shares in the company, valued at approximately $170,299.80. This trade represents a 83.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Renato Tamaro sold 3,204 shares of the stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $249.24, for a total value of $798,564.96. Following the completion of the transaction, the vice president owned 7,221 shares of the company’s stock, valued at $1,799,762.04. This represents a 30.73% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 18,868 shares of company stock worth $4,585,389 over the last quarter. 1.07% of the stock is currently owned by company insiders.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.